Business Description
Soleno Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US8342033094
Description
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 84.77 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34 | |||||
| 3-Year FCF Growth Rate | 37 | |||||
| 3-Year Book Growth Rate | -16.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 50.38 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.45 | |||||
| 9-Day RSI | 58.44 | |||||
| 14-Day RSI | 57.97 | |||||
| 6-1 Month Momentum % | 41.86 | |||||
| 12-1 Month Momentum % | 132.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.26 | |||||
| Quick Ratio | 17.26 | |||||
| Cash Ratio | 17.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -81.4 | |||||
| Shareholder Yield % | -4.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -75.42 | |||||
| ROA % | -64.68 | |||||
| ROIC % | -452.37 | |||||
| 3-Year ROIIC % | 376.95 | |||||
| ROC (Joel Greenblatt) % | -14581.82 | |||||
| ROCE % | -73.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 8.86 | |||||
| Price-to-Tangible-Book | 9.11 | |||||
| EV-to-EBIT | -15.95 | |||||
| EV-to-Forward-EBIT | -22.31 | |||||
| EV-to-EBITDA | -16.18 | |||||
| EV-to-Forward-Revenue | 65.08 | |||||
| EV-to-FCF | -42.78 | |||||
| Price-to-Net-Current-Asset-Value | 10.36 | |||||
| Price-to-Net-Cash | 10.42 | |||||
| Earnings Yield (Greenblatt) % | -6.27 | |||||
| FCF Yield % | -2.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Soleno Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.049 | ||
| Beta | -2.81 | ||
| Volatility % | 104.49 | ||
| 14-Day RSI | 57.97 | ||
| 14-Day ATR (€) | 1.888976 | ||
| 20-Day SMA (€) | 48.94 | ||
| 12-1 Month Momentum % | 132.74 | ||
| 52-Week Range (€) | 20.1 - 52.7 | ||
| Shares Outstanding (Mil) | 43.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Soleno Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Soleno Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Soleno Therapeutics Inc Frequently Asked Questions
What is Soleno Therapeutics Inc(FRA:6XC)'s stock price today?
The current price of FRA:6XC is €50.85. The 52 week high of FRA:6XC is €52.70 and 52 week low is €20.10.
When is next earnings date of Soleno Therapeutics Inc(FRA:6XC)?
The next earnings date of Soleno Therapeutics Inc(FRA:6XC) is 2024-11-08 Est..
Does Soleno Therapeutics Inc(FRA:6XC) pay dividends? If so, how much?
Soleno Therapeutics Inc(FRA:6XC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers